Feb112021 Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook February 11, 2021
Feb82021 Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021 February 8, 2021
Dec282020 Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates December 28, 2020
Dec222020 Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020 December 22, 2020
Dec212020 Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thalmann & Co. December 21, 2020
Dec152020 Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome December 15, 2020
Nov252020 Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference November 25, 2020
Nov62020 Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference November 6, 2020
Oct152020 Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia October 15, 2020
Sep102020 Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial September 10, 2020
Sep82020 Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Global Investment Conference September 8, 2020
Aug192020 Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinson’s Disease August 19, 2020
